Physician

Akash Nair Sethi, D.O.

According to 2025 Medicare claims, Akash Sethi, D.O. (NPI: 1558620575) practices nephrology in the Philadelphia, PA market, with the plurality of this provider's patient population coming from Philadelphia, PA. This provider's primary affiliated billing organization is KIDNEY CARE SPECIALISTS LLC (NPI: 1962992404; TIN: 82-4435212) and primary practice location at 19118-3541.

Sethi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 419 traditional Medicare patients, billed 1,860 HCPCS/CPT codes, and received $220,227 in Medicare payments. The top billing code was 99233 (Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes). Part D data shows 1,022 prescription claims across 180 beneficiaries totaling $247,384 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 119 claims. Open Payments data shows 11 records totaling $235. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $22,949 to $247,384. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	183	757	$81,969
2018	401	2,215	$249,043
2019	428	1,847	$237,268
2020	499	1,905	$250,530
2021	466	1,754	$250,596
2022	487	1,861	$245,098
2023	455	1,653	$228,718
2024	419	1,860	$220,227

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	69	415	$22,949
2016	30	144	$9,626
2017	31	104	$3,754
2018	96	387	$75,613
2019	119	738	$193,791
2020	120	620	$197,642
2021	136	649	$204,325
2022	183	1,374	$353,171
2023	178	1,287	$348,610
2024	180	1,022	$247,384

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	105	$14,039
2022	N/R	261	$35,718
2023	N/R	147	$21,279
2024	N/R	119	$15,362

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	82	206	$95
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	80	118	$78
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	116	156	$78
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	99	202	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	165	263	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	60	2,460	$44,593
Auryxia	Ferric Citrate	36	1,260	$44,207
Velphoro	Sucroferric Oxyhydroxide	17	570	$43,785
Cinacalcet Hcl	Cinacalcet Hcl	41	1,470	$42,377
Jardiance	Empagliflozin	12	360	$6,857

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	23	$13,432
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	20	$561
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	41	$502
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	13	$472
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	22	$395

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$235	Ardelyx, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Akash Nair Sethi, D.O.?

Tedicare shows public-source Medicare data for Akash Nair Sethi, D.O. (NPI 1558620575), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Akash Nair Sethi, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Akash Nair Sethi, D.O.?

Akash Nair Sethi, D.O. is linked to KIDNEY CARE SPECIALISTS LLC (billing NPI 1962992404) in the available physician profile data.

Does Akash Nair Sethi, D.O. have Open Payments data?

Akash Nair Sethi, D.O. has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.